Selenoglycoproteins attenuate adhesion of tumor cells to the brain microvascular endothelium via a process involving NF-κB activation

Jagoda K. Wrobel, Jeong June Choi, Rijin Xiao, Sung Yong Eum, Stefan Kwiatkowski, Gretchen Wolff, Leya Spangler, Ronan F. Power, Michal J Toborek

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Selenium-containing compounds and selenized yeast have anticancer properties. In order to address possible mechanisms involved in these effects, selenoglycoproteins (SGPs) were extracted from selenium-enriched yeast at pH 4.0 and 6.5 (the fractions are called SGP40 and SGP65, respectively), followed by evaluation of their impact on the interactions of lung and breast tumor cells with human brain microvascular endothelial cells (HBMECs). Extracted SGPs, especially SGP40, significantly inhibited adhesion of tumor cells to HBMECs and their transendothelial migration. Because the active components of SGPs are unknown, small selenium-containing compounds [leucyl-valyl-selenomethionyl-arginine (LVSe-MR) and methylselenoadenosine (M-Se-A)], which are normally present in selenized yeast, were introduced as additional treatment groups. Treatment of HBMECs with SGP40, LVSe-MR and M-Se-A induced changes in gene signatures, which suggested a central involvement of nuclear factor (NF)-κB-dependent pathway. These observations were confirmed in the subsequent analysis of NF-κB DNA binding activity, quantitative measurements of the expression of selected genes and proteins, and tumor cell adhesion assay with a specific NF-κB inhibitor as the additional treatment factor. These findings indicate that specific organic selenium-containing compounds have the ability to inhibit tumor cell adhesion to brain endothelial cells via down-regulation of NF-κB. SGPs appear to be more effective than small selenium-containing compounds, suggesting the role of not only selenium but also the glycoprotein component in the observed protective impact.

Original languageEnglish
Pages (from-to)120-129
Number of pages10
JournalJournal of Nutritional Biochemistry
Volume26
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Selenium Compounds
Selenium
Cell Adhesion
Endothelium
Tumors
Brain
Adhesion
Endothelial Cells
Chemical activation
Endothelial cells
Cells
Yeasts
Yeast
Neoplasms
Cell adhesion
Transendothelial and Transepithelial Migration
Arginine
Glycoproteins
Down-Regulation
Breast Neoplasms

Keywords

  • Adhesion
  • Brain
  • NF-κB
  • Selenium
  • Transendothelial migration
  • Tumor cell motility

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Molecular Biology
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Cite this

Selenoglycoproteins attenuate adhesion of tumor cells to the brain microvascular endothelium via a process involving NF-κB activation. / Wrobel, Jagoda K.; Choi, Jeong June; Xiao, Rijin; Eum, Sung Yong; Kwiatkowski, Stefan; Wolff, Gretchen; Spangler, Leya; Power, Ronan F.; Toborek, Michal J.

In: Journal of Nutritional Biochemistry, Vol. 26, No. 2, 01.02.2015, p. 120-129.

Research output: Contribution to journalArticle

Wrobel, Jagoda K. ; Choi, Jeong June ; Xiao, Rijin ; Eum, Sung Yong ; Kwiatkowski, Stefan ; Wolff, Gretchen ; Spangler, Leya ; Power, Ronan F. ; Toborek, Michal J. / Selenoglycoproteins attenuate adhesion of tumor cells to the brain microvascular endothelium via a process involving NF-κB activation. In: Journal of Nutritional Biochemistry. 2015 ; Vol. 26, No. 2. pp. 120-129.
@article{a0379105577f4227b550479fa0c85373,
title = "Selenoglycoproteins attenuate adhesion of tumor cells to the brain microvascular endothelium via a process involving NF-κB activation",
abstract = "Selenium-containing compounds and selenized yeast have anticancer properties. In order to address possible mechanisms involved in these effects, selenoglycoproteins (SGPs) were extracted from selenium-enriched yeast at pH 4.0 and 6.5 (the fractions are called SGP40 and SGP65, respectively), followed by evaluation of their impact on the interactions of lung and breast tumor cells with human brain microvascular endothelial cells (HBMECs). Extracted SGPs, especially SGP40, significantly inhibited adhesion of tumor cells to HBMECs and their transendothelial migration. Because the active components of SGPs are unknown, small selenium-containing compounds [leucyl-valyl-selenomethionyl-arginine (LVSe-MR) and methylselenoadenosine (M-Se-A)], which are normally present in selenized yeast, were introduced as additional treatment groups. Treatment of HBMECs with SGP40, LVSe-MR and M-Se-A induced changes in gene signatures, which suggested a central involvement of nuclear factor (NF)-κB-dependent pathway. These observations were confirmed in the subsequent analysis of NF-κB DNA binding activity, quantitative measurements of the expression of selected genes and proteins, and tumor cell adhesion assay with a specific NF-κB inhibitor as the additional treatment factor. These findings indicate that specific organic selenium-containing compounds have the ability to inhibit tumor cell adhesion to brain endothelial cells via down-regulation of NF-κB. SGPs appear to be more effective than small selenium-containing compounds, suggesting the role of not only selenium but also the glycoprotein component in the observed protective impact.",
keywords = "Adhesion, Brain, NF-κB, Selenium, Transendothelial migration, Tumor cell motility",
author = "Wrobel, {Jagoda K.} and Choi, {Jeong June} and Rijin Xiao and Eum, {Sung Yong} and Stefan Kwiatkowski and Gretchen Wolff and Leya Spangler and Power, {Ronan F.} and Toborek, {Michal J}",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/j.jnutbio.2014.09.013",
language = "English",
volume = "26",
pages = "120--129",
journal = "Journal of Nutritional Biochemistry",
issn = "0955-2863",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Selenoglycoproteins attenuate adhesion of tumor cells to the brain microvascular endothelium via a process involving NF-κB activation

AU - Wrobel, Jagoda K.

AU - Choi, Jeong June

AU - Xiao, Rijin

AU - Eum, Sung Yong

AU - Kwiatkowski, Stefan

AU - Wolff, Gretchen

AU - Spangler, Leya

AU - Power, Ronan F.

AU - Toborek, Michal J

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Selenium-containing compounds and selenized yeast have anticancer properties. In order to address possible mechanisms involved in these effects, selenoglycoproteins (SGPs) were extracted from selenium-enriched yeast at pH 4.0 and 6.5 (the fractions are called SGP40 and SGP65, respectively), followed by evaluation of their impact on the interactions of lung and breast tumor cells with human brain microvascular endothelial cells (HBMECs). Extracted SGPs, especially SGP40, significantly inhibited adhesion of tumor cells to HBMECs and their transendothelial migration. Because the active components of SGPs are unknown, small selenium-containing compounds [leucyl-valyl-selenomethionyl-arginine (LVSe-MR) and methylselenoadenosine (M-Se-A)], which are normally present in selenized yeast, were introduced as additional treatment groups. Treatment of HBMECs with SGP40, LVSe-MR and M-Se-A induced changes in gene signatures, which suggested a central involvement of nuclear factor (NF)-κB-dependent pathway. These observations were confirmed in the subsequent analysis of NF-κB DNA binding activity, quantitative measurements of the expression of selected genes and proteins, and tumor cell adhesion assay with a specific NF-κB inhibitor as the additional treatment factor. These findings indicate that specific organic selenium-containing compounds have the ability to inhibit tumor cell adhesion to brain endothelial cells via down-regulation of NF-κB. SGPs appear to be more effective than small selenium-containing compounds, suggesting the role of not only selenium but also the glycoprotein component in the observed protective impact.

AB - Selenium-containing compounds and selenized yeast have anticancer properties. In order to address possible mechanisms involved in these effects, selenoglycoproteins (SGPs) were extracted from selenium-enriched yeast at pH 4.0 and 6.5 (the fractions are called SGP40 and SGP65, respectively), followed by evaluation of their impact on the interactions of lung and breast tumor cells with human brain microvascular endothelial cells (HBMECs). Extracted SGPs, especially SGP40, significantly inhibited adhesion of tumor cells to HBMECs and their transendothelial migration. Because the active components of SGPs are unknown, small selenium-containing compounds [leucyl-valyl-selenomethionyl-arginine (LVSe-MR) and methylselenoadenosine (M-Se-A)], which are normally present in selenized yeast, were introduced as additional treatment groups. Treatment of HBMECs with SGP40, LVSe-MR and M-Se-A induced changes in gene signatures, which suggested a central involvement of nuclear factor (NF)-κB-dependent pathway. These observations were confirmed in the subsequent analysis of NF-κB DNA binding activity, quantitative measurements of the expression of selected genes and proteins, and tumor cell adhesion assay with a specific NF-κB inhibitor as the additional treatment factor. These findings indicate that specific organic selenium-containing compounds have the ability to inhibit tumor cell adhesion to brain endothelial cells via down-regulation of NF-κB. SGPs appear to be more effective than small selenium-containing compounds, suggesting the role of not only selenium but also the glycoprotein component in the observed protective impact.

KW - Adhesion

KW - Brain

KW - NF-κB

KW - Selenium

KW - Transendothelial migration

KW - Tumor cell motility

UR - http://www.scopus.com/inward/record.url?scp=84921031268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921031268&partnerID=8YFLogxK

U2 - 10.1016/j.jnutbio.2014.09.013

DO - 10.1016/j.jnutbio.2014.09.013

M3 - Article

C2 - 25465156

AN - SCOPUS:84921031268

VL - 26

SP - 120

EP - 129

JO - Journal of Nutritional Biochemistry

JF - Journal of Nutritional Biochemistry

SN - 0955-2863

IS - 2

ER -